Search results for "Combination"

showing 10 items of 1379 documents

Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.

1991

A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer. The overall response rate was 27% with a mean duration of more than 10.2 months. A stabilization with a mean duration of 5.1 months was seen in 56% of cases, while 20% of patients progressed. Gastrointestinal toxicity, mostly grade 1 or 2 nausea/vomiting was seen in 85% of cases, grade 1 or 2 leukopenia in 60% of patients, and grade 1 or 2 thrombocytopenia in 42%. Considering the good compliance of this regimen and the poor prognosis of patients with refractory advanced breast cancer, this combination can be useful as a palliative treatment of breast carcin…

MelphalanOncologyAdultCancer Researchmedicine.medical_specialtyVindesinemedicine.medical_treatmentMitomycinBreast NeoplasmsMitomycinsBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasisMelphalanAgedChemotherapybusiness.industryMitomycin CPalliative CareCancerCombination chemotherapyGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerOncologyVindesineFemalebusinessmedicine.drugJournal of cancer research and clinical oncology
researchProduct

Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy.

2000

OBJECTIVE: To characterize the effects of anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing regimens with dosages ·50 mg·m−2. METHODS: A prospective, cross-sectional, noncontrolled study was performed to analyze acute vomiting during the first 24 hours in patients treated in a Spanish hospital. The patients received an intravenous combination of drugs (2 doses of metoclopramide 3 mg/kg, dexamethasone 20 mg) as first-choice antiemetic therapy. Intravenous ondansetron 8 mg and dexamethasone 20 mg served as an alternative regimen in patients <30 years old with a history of extrapyramidal manifestations or emesis in previous cycles. Therapeutic …

Metoclopramidemedicine.drug_classChlorpromazineMetoclopramideVomitingmedicine.medical_treatmentAntineoplastic Agents030204 cardiovascular system & hematology030226 pharmacology & pharmacyDexamethasoneOndansetron03 medical and health sciences0302 clinical medicineSex FactorsOrphenadrinemedicineAntiemeticHumansPharmacology (medical)Body Weights and MeasuresProspective StudiesDexamethasoneChemotherapybusiness.industryAge FactorsMiddle AgedPrognosisOndansetronRegimenDrug CombinationsCross-Sectional StudiesLogistic ModelsAnesthesiaAcute DiseaseMultivariate AnalysisVomitingCorticosteroidAntiemeticsmedicine.symptomCisplatinbusinessmedicine.drugThe Annals of pharmacotherapy
researchProduct

Contribution of outgrowth endothelial cells from human peripheral blood on in vivo vascularization of bone tissue engineered constructs based on star…

2009

In the present study we assessed the potential of human outgrowth endothelial cells (OEC), a subpopulation within endothelial progenitor cell cultures, to support the vascularization of a complex tissue engineered construct for bone. OEC cultured on starch polycaprolactone fiber meshes (SPCL) in monoculture retained their endothelial functionality and responded to angiogenic stimulation by VEGF (vascular endothelial growth factor) in fibrin gel-assays in vitro. Co-culture of OEC with human primary osteoblasts (pOB) on SPCL, induced an angiogenic activation of OEC towards microvessel-like structures achieved without additional supplementation with angiogenic growth factors. Effects of co-cul…

Mice SCID02 engineering and technologyBone tissueBone tissue engineeringNeovascularizationMicechemistry.chemical_compoundSubcutaneous TissueImplants ExperimentalTissue engineeringOsteogenesisEndothelial progenitor cells0303 health sciencesIn vivo testTissue ScaffoldsbiologyStarch021001 nanoscience & nanotechnology3. Good healthCell biologyVascular endothelial growth factorDrug CombinationsPhenotypemedicine.anatomical_structureMechanics of MaterialsProteoglycansCollagenmedicine.symptom0210 nano-technologyPolyestersBiophysicsNeovascularization PhysiologicBioengineeringEndothelial progenitor cellBone and BonesFibrinBiomaterials03 medical and health sciencesIn vivomedicineAnimalsHumansCell Proliferation030304 developmental biologyMatrigelScience & TechnologyOsteoblastsTissue EngineeringVascularizationEndothelial CellsCoculture TechniquesGene Expression RegulationchemistryCeramics and Compositesbiology.proteinLamininBiomedical engineeringBiomaterials
researchProduct

Investigation of a tunnel pasteurizer for “Nocellara del Belice” table olives processed according to the “Castelvetrano method”

2014

The influence of pasteurization temperature and time of treatment on the flesh firmness and the evolution of microbial communities was studied for table olives Cv. Nocellara del Belice, packed in glass jars and processed with a tunnel pasteurizer. The experiment was first carried out on the laboratory level in order to select the optimal combination of pasteurization time/temperature so as to obtain the proper balance between the consistency of the pulp and the microbiological quality of the final product. Pasteurization at industrial scale was then carried out in a tunnel pasteurizer applying the treatment at 75 °C for 8 min in the thermal center of the jars. Besides flesh firmness and mic…

Microbiological analysisAnálisis microbiológicoTexturaMineralogyPasteurizationTitratable acidlcsh:TX341-641engineering.materiallaw.inventionDynamometerlawOptimal combinationTable (landform)TX341-641TextureSofteningDinamómetroTable olivesNutrition. Foods and food supplyFleshPulp (paper)Organic ChemistrySettore AGR/09 - Meccanica AgrariaCompression forceMicrobiological qualityHorticulturecompression force dynamometer microbiological analysis table olives texture tunnel pasteurizerTunnel pasteurizerPasteurizador de túnelengineeringEnvironmental scienceAceitunas de mesaFuerza de compresiónlcsh:Nutrition. Foods and food supplyFood ScienceGrasas y Aceites
researchProduct

Toxoplasmosis after hematopoietic stem cell transplantation.

2000

In immunocompromised individuals, toxoplasmosis mostly occurs as a reactivation of a latent infection, causing severe to life-threatening disease. Thus, recipients who are seropositive for Toxoplasma gondii before an allogeneic hematopoietic stem cell transplant (HCT) are at highest risk, although primary infections may also cause severe toxoplasmosis. The disease most often affects the central nervous system, but in HCT recipients other organs are involved in more than half of the cases. Because of the alteration of the immune response in these patients, serodiagnosis is not sufficiently reliable in the diagnosis of post-HCT toxoplasmosis, and direct detection of the causative agent is req…

Microbiology (medical)AdultMaleAdolescentmedicine.medical_treatmentAntiprotozoal AgentsSulfadiazineHematopoietic stem cell transplantationDiseasePharmacotherapyImmunopathologyTrimethoprim Sulfamethoxazole Drug CombinationmedicineAnimalsHumansChildSurvival ratebiologybusiness.industryClindamycinHematopoietic Stem Cell TransplantationToxoplasma gondiiMiddle Agedmedicine.diseasebiology.organism_classificationToxoplasmosisTransplantationSurvival RateInfectious DiseasesPyrimethamineImmunologyDrug Therapy CombinationFemaleAutopsybusinessToxoplasmaToxoplasmosisClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Evolutionary dynamics of the E1-E2 viral populations during combination therapy in non-responder patients chronically infected with hepatitis C virus…

2012

Abstract Half of the patients chronically infected with hepatitis C virus (HCV) genotype 1 fail to respond to pegylated interferon alpha (PEG-IFN) and ribavirin (RBV) therapy. This study assesses the effects of treatment on the evolution of the E1–E2 viral region in non-responder patients infected with HCV-1b. Twenty-three HCV-1b chronically infected patients were studied retrospectively, including 19 non-responders to PEG-IFN/RBV therapy (11 null-responders and 8 relapsers) in the study group, and 4 untreated patients in the control group. Genetic and phylogenetic analyses of the E1–E2 viral populations were performed at baseline and at the time of treatment failure to assess changes in ge…

Microbiology (medical)AdultMaleCombination therapyHepatitis C virusAdaptation BiologicalHepacivirusBiologymedicine.disease_causeMicrobiologyAntiviral AgentsEvolution Molecularchemistry.chemical_compoundViral Envelope ProteinsPegylated interferonGenotypeGeneticsmedicineHumansGenetic variabilityTreatment FailureMolecular BiologyEcology Evolution Behavior and SystematicsPhylogenyAgedRetrospective StudiesGenetic diversityRibavirinGenetic VariationHepatitis C ChronicMiddle AgedViral LoadVirologyInfectious DiseaseschemistryAmino Acid SubstitutionViral evolutionImmunologyDrug Therapy CombinationFemalemedicine.drugInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
researchProduct

Toxoplasmosis, a severe complication in allogeneic hematopoietic stem cell transplantation: successful treatment strategies during a 5-year single-ce…

1999

Toxoplasmosis is a rare but often fatal complication that occurs after patients undergo allogeneic hematopoietic stem cell transplant. At our institution, toxoplasmosis was diagnosed in 8 of 301 patients who received stem cell transplants. Disseminated toxoplasmosis with a rapid fatal course was observed in 2 patients. Six patients had cerebral toxoplasmosis diagnosed on the basis of neurological signs and observation of the patients' mental confusion, seizures, and typical lesions (which were assessed by computed tomography, magnetic resonance imaging, or both). Seroconversion of antitoxoplasma immunoglobulin and a discovery of toxoplasma deoxyribonucleic acid in the cerebrospinal fluid (c…

Microbiology (medical)AdultMalePathologymedicine.medical_specialtyPediatricsmedicine.medical_treatmentAntibodies ProtozoanSulfadiazineHematopoietic stem cell transplantationSingle CenterPharmacotherapySulfadiazinemedicineAnimalsHumansTransplantation HomologousSeroconversionbusiness.industryClindamycinHematopoietic Stem Cell TransplantationMiddle Agedmedicine.diseaseMagnetic Resonance ImagingToxoplasmosisTransplantationInfectious DiseasesPyrimethamineImmunoglobulin MToxoplasmosis CerebralDrug Therapy CombinationFemalebusinessComplicationTomography X-Ray ComputedToxoplasmamedicine.drugClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing k. pneumoniae infections: A retrospective observational multicenter study

2021

Abstract Background A growing body of observational evidence supports the value of ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae. Methods We retrospectively analyzed observational data on use and outcomes of CAZ-AVI therapy for infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. Results The cohort comprised 577 adults with bloodstream infections (n = 391) or nonba…

Microbiology (medical)Adultmedicine.medical_specialtyAzabicyclo CompoundcarbapenemasesBacterial ProteinMicrobial Sensitivity TestsNeutropeniaCeftazidimebeta-Lactamasesbeta-LactamaseCarbapenemasecarbapenemaseBacterial ProteinsRetrospective StudieLower respiratory tract infectionInternal medicineDrug CombinationAnti-Bacterial AgentmedicineHumansKPC-producing Klebsiella pneumoniaeRetrospective StudiesSeptic shockbusiness.industryCeftazidime-avibactamMicrobial Sensitivity Testceftazidime-avibactamMortality rateCarbapenemases; Ceftazidime-avibactam; KPC-producing Klebsiella pneumoniae; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeKPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactammedicine.diseaseCeftazidime/avibactamSettore MED/17KPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactam; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeAnti-Bacterial AgentsKlebsiella InfectionsDrug CombinationsKlebsiella pneumoniaeInfectious DiseasesCohortPropensity score matchingObservational studybusinessAzabicyclo Compoundsmedicine.drugHumanKlebsiella Infection
researchProduct

Combination of aztreonam, ceftazidime–avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis

2021

Abstract We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the blaVIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time-kill curves showed that this triple antibiotic combination at 1 × MIC was strongly synergic after 8 h, achieving 99.9% killing and maintaining this until 48 h.

Microbiology (medical)AvibactamDrug ResistanceCeftazidimeInfectious and parasitic diseasesRC109-216Aztreonammedicine.disease_causeST235CeftazidimeMicrobiologyCeftazidime–avibactamchemistry.chemical_compoundAztreonamAortic valve replacementDrug TherapyDrug Resistance Multiple BacterialmedicineHumansPseudomonas InfectionsPseudomonas aeruginosa; ST235; VIM-1; aztreonam; ceftazidime-avibactam; osteomyelitisAmikacinAgedPseudomonas aeruginosabusiness.industryceftazidime-avibactamOsteomyelitisBacterialOsteomyelitisGeneral MedicineCeftazidime/avibactammedicine.diseaseAnti-Bacterial AgentsDrug CombinationsInfectious DiseaseschemistryDebridementAmikacinPseudomonas aeruginosaCombinationVIM-1Drug Therapy CombinationFemalebusinessAzabicyclo CompoundsMultiplemedicine.drug
researchProduct

Mixed vaginal infections of Balb/c mice with low virulent herpes simplex type 1 strains result in restoration of virulence properties: vaginitis/vulv…

1997

Vaginal infections of BALB/c Ann mice with herpes simplex virus type 1 (HSV-1) were studied. Mice were inoculated with virulent strains ANG path and 17 syn+ or low-virulent recombinant strains 27/III and 17-syn3 that differ from parental strains in their glycoprotein B (gB) gene sequences. When low-virulent strains were inoculated separately, no vaginitis/vulvitis was produced despite replication in the vagina. In contrast, after coinfection of mice with the two low-virulent strains, vaginitis/vulvitis was produced and virus could be recovered from the central nervous system (CNS). Two of the CNS isolates produced vaginitis/vulvitis, neuroinvasiveness and death of mice after vaginal infecti…

Microbiology (medical)Central Nervous SystemImmunologyMolecular Sequence DataVirulenceHerpesvirus 1 Humanmedicine.disease_causePolymerase Chain ReactionVirusBALB/cMicrobiologyMiceVaginal diseasemedicineImmunology and AllergyAnimalsAmino Acid SequenceEncephalomyelitisVaginitisRecombination GeneticMice Inbred BALB CbiologyGeneral MedicineSequence Analysis DNAmedicine.diseasebiology.organism_classificationVulvovaginitisVirologyHerpes simplex virusVulvitisCoinfectionFemalemedicine.symptomMedical microbiology and immunology
researchProduct